(Press-News.org)
VIDEO:
Dr. James Bradner talks about how he and other researchers at Dana-Farber Cancer Institute and Baylor College of Medicine used a small molecule compound to generate reversible birth control in...
Click here for more information.
BOSTON—The development of a male contraceptive pill has long proven to be elusive, but findings from a new study may point scientists in the right direction to making oral birth control for men a reality.
Researchers at Dana-Farber Cancer Institute and Baylor College of Medicine report in the Aug. 17 issue of Cell that they have used a small molecule compound to generate reversible birth control in male mice.
The compound, called JQ1, penetrates the blood-testis boundary to disrupt spermatogenesis, the process by which sperm develop to become mature sperm. The result is a decrease in the number and quality of sperm. The study showed that normal sperm production resumed when JQ1 was discontinued, and JQ1 did not affect testosterone production, mating behavior, or the health of offspring conceived after JQ1 use.
"Our findings demonstrate that, when given to rodents, this compound produces a rapid and reversible decrease in sperm count and mobility with profound effects on fertility," said Dana-Farber's James Bradner, MD, the paper's senior author.
Martin Matzuk, MD, PhD, of Baylor College of Medicine, is the paper's first author.
JQ1 was originally synthesized at Dana-Farber to block BRD4, a cancer-causing gene. Named for the lead chemist, Jun Qi, PhD, in the Bradner laboratory, JQ1 has proven effective in models of lung cancer and in several blood cancers including leukemia and multiple myeloma. During the past two years, the Bradner group has provided JQ1 without charge to more than 350 laboratories around the world.
The Dana-Farber/Baylor collaboration started when Bradner told Matzuk that he was testing JQ1 as an inhibitor of a member of a family of bromodomain proteins, and he wanted to know whether JQ1 would have an effect on a spermatogenic-specific member of that family called BRDT. This question was based on earlier research from Debra Wolgemuth, PhD, and her group at Columbia University that revealed that mice lacking BRDT were infertile.
BRDT is involved in the chromatin remodeling process during the generation of sperm in the testis. Chromatin is the combination of DNA and proteins that make up the contents of the nucleus of a cell. It is "remodeled" to give the proteins that regulate how genes act access to the genetic material.
JQ1 subverts that process by binding to a pocket of BRDT that is necessary for chromatin remodeling to take place. In doing this, JQ1 blocks the normal process by which sperm are made, thereby reducing production and quality of the sperm.
Using JQ1 provided by Bradner, Matzuk and his group injected mice with the compound in solution and evaluated the effect. The mice that received JQ1 had lower sperm counts, and their sperm were less mobile than those of mice who had not received the molecule. This rendered the JQ1-treated mice infertile.
"These findings suggest that a reversible, oral male contraceptive may be possible," said Bradner, who is also on faculty at Harvard Medical School and the Broad Institute. "While we will be conducting more research to see if we can build on our current findings, JQ1 shows initial promise as a lead compound for male contraception."
INFORMATION:
In addition to Bradner and Matzuk, others who contributed are Michael R. McKeown, Madeleine E. Lemieux, PhD, and Jun Qi, PhD of Dana-Farber; Panagis Filippakopoulos, PhD, Sarah Picaud, PhD, and Stefan Knapp, PhD, of the University of Oxford in the UK; Qinglei Li, MD, PhD, of Texas A&M University in College Station; Lang Ma, PhD, and Julio E. Agno of Baylor College of Medicine; and Richard N. Yu, MD, PhD, of Boston Children's Hospital.
These studies were supported, in part, by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (U01-HD060496); the Burroughs Wellcome Fund; the National Institutes of Health (K08CA128972), the Smith Family Foundation, and Damon-Runyon Cancer Research Foundation.
Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center, designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women's Hospital as Dana-Farber/Brigham and Women's Cancer Center and it provides pediatric care with Boston Children's Hospital as Dana-Farber/Children's Hospital Cancer Center. Dana-Farber is the top ranked cancer center in New England and fifth nationally, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding.
Follow Dana-Farber on Twitter:
@danafarber
or Facebook:
facebook.com/danafarbercancerinstitute.
EDITOR'S NOTE: A video interview with Dr. Bradner, lab b-roll and animation is available upon request.
A male contraceptive pill in the making?
2012-08-16
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Discovery of immune cells that protect against multiple sclerosis offers hope for new treatment
2012-08-16
In multiple sclerosis, the immune system attacks nerves in the brain and spinal cord, causing movement problems, muscle weakness and loss of vision. Immune cells called dendritic cells, which were previously thought to contribute to the onset and development of multiple sclerosis, actually protect against the disease in a mouse model, according to a study published by Cell Press in the August issue of the journal Immunity. These new insights change our fundamental understanding of the origins of multiple sclerosis and could lead to the development of more effective treatments ...
Scripps Research scientists find an important molecular trigger for wound-healing
2012-08-16
LA JOLLA, CA – August 16, 2012 – Scientists at The Scripps Research Institute have made a breakthrough in understanding a class of cells that help wounds in skin and other epithelial tissues heal, uncovering a molecular mechanism that pushes the body into wound-repair mode.
The findings, which appear in an advance, online version of the Immunity on August 16, 2012, focus on cells known as γδ (gamma delta) T cells. The new study demonstrates a skin-cell receptor hooks up with a receptor on γδ T-cells to stimulate wound healing.
"This is a major activation ...
Invasive brittle star species hits Atlantic Ocean
2012-08-16
Coral Reefs, the Journal of the International Society for Reef Studies, has published online a study co-written by Dr. Gordon Hendler of the Natural History Museum of Los Angeles County (NHM) about an invasive species of brittle star, Ophiothela mirabilis. The species was previously restricted to Pacific waters, but surprisingly, growing populations have established themselves at distant points in the Atlantic. Its presence near Brazilian and Caribbean ports indicates that O. mirabilis could have been spread by shipping.
The marine animal is colorful and six-rayed. It ...
Some like it hot: Tropical species 'not as vulnerable' to climate change extinction
2012-08-16
In the face of a changing climate many species must adapt or perish. Ecologists studying evolutionary responses to climate change forecast that cold-blooded tropical species are not as vulnerable to extinction as previously thought. The study, published in the British Ecological Society's Functional Ecology, considers how fast species can evolve and adapt to compensate for a rise in temperature.
The research, carried out at the University of Zurich, was led by Dr Richard Walters, now at Reading University, alongside David Berger now at Uppsala University and Wolf Blanckenhorn, ...
Yoga: A cost-effective treatment for back pain sufferers?
2012-08-16
Specialised group yoga classes could provide a cost-effective way of treating patients with chronic or recurrent low back pain, according to the UK's largest ever study of the benefits of yoga.
Led by the University of York, and funded by Arthritis Research UK, the study provides an evaluation of a specially-developed 12-week group yoga intervention programme compared to conventional general practitioner (GP) care alone.
The results published in Spine, show that the yoga intervention programme – 'Yoga for Healthy Lower Backs' - is likely to be cost effective for both ...
Tibetan Plateau may be older than previously thought
2012-08-16
The growth of high topography on the Tibetan Plateau in Sichuan, China, began much earlier than previously thought, according to an international team of geologists who looked at mountain ranges along the eastern edge of the plateau.
The Indian tectonic plate began its collision with Asia between 55 and 50 million years ago, but "significant topographic relief existed adjacent to the Sichuan Basin prior to the Indo-Asian collision," the researchers report online in Nature Geoscience.
"Most researchers have thought that high topography in eastern Tibet developed during ...
Added benefit of eribulin in breast cancer is not proven
2012-08-16
Eribulin (trade name: Halaven®) was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy.
In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether eribulin offers an added benefit compared with the present standard therapy.
According to the results of the assessment, the currently available evidence provides "hints" that eribulin ...
Ohioans love their lakes, but are concerned for their future
2012-08-16
COLUMBUS, Ohio - Almost 41 percent of Ohioans have visited a lake, pond, river or creek in the state in the past year, and of those, nearly one-half usually spend their water-related recreational time at Lake Erie, according to preliminary findings in a new report.
These figures and other findings in the report suggest that Ohio residents value their lakes and rivers, and particularly Lake Erie, as natural resources, but also help to clarify the risk that Ohioans face from contaminants in those same bodies of water, researchers say.
Among the risks: Some blue-green ...
RI Hospital: Use of PMP may increase demand for drug treatment, reduce painkiller abuse
2012-08-16
PROVIDENCE, R.I. – A Rhode Island Hospital researcher has found that the use of electronic prescription drug monitoring programs (PMPs) may have a significant impact on the demand for drug treatment programs and how prescribers detect and respond to abuse of painkillers. The study by Traci C. Green, Ph.D., MSc, research scientist in Rhode Island Hospital's department of general internal medicine, is published online in advance of print in the journal Pain Medicine.
The study surveyed 1,385 providers in Rhode Island and Connecticut on their use of state PMPs, and found ...
Enzalutamide adds 5 months survival in late-stage prostate cancer
2012-08-16
Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.
"This is a major advance. Not only do we see more survival benefit than from traditional chemotherapy, but the side effects of Enzalutamide are much lower. It provides both more benefit and less harm – you get the quantification of more life, but also see quality of life improvements," says study co-author, Thomas Flaig, MD, medical director of the ...